Sugi Predict

Sugi Predict / Compounds / SCHEMBL78026

SCHEMBL78026

SCHEMBL78026

COC1(C)CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ HPGD P15428 1/20 0.44
▸ EPHX2 P34913 1/20 0.43
▸ RECQL P46063 1/20 0.42
▸ EPHX1 P07099 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.41
▸ LMNA P02545 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ ALOX15 P16050 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ GPR119 Q8TDV5 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20228010 0.90 USP2 (0.45) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL22418457 0.88 USP2 (0.47) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL31566523 0.85 USP2 (0.39) USP2SMN1; SMN2HPGDEPHX2
SCHEMBL3436829 0.83 USP2 (0.56) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL22275096 0.83 USP2 (0.49) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL27694592 0.83 USP2 (0.49) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL24214082 0.82 USP2 (0.45) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL78071 0.81 USP2 (0.55) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL71597 0.81 USP2 (0.46) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL24203222 0.81 USP2 (0.47) USP2SMN1; SMN2HPGDEPHX2RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3233077-B1 DOPAMINE D2 RECEPTOR LIGANDS BROAD INST INC (US) 2026-05-06 — — EP disclosed
US-12428373-B2 Dopamine D2 receptor ligands THE BROAD INSTITUTE, INC. (US) 2025-09-30 — — US disclosed
US-20230183237-A1 COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 VANDERBILT UNIVERSITY 2023-06-15 — — US disclosed
US-20230143552-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2023-05-11 — — US disclosed
US-20230143552-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2023-05-11 — — US disclosed
CN-111471059-B PDE9 inhibitors and uses thereof 药捷安康(南京)科技股份有限公司 2022-12-02 — — CN disclosed
US-11498896-B2 Dopamine D2 receptor ligands THE BROAD INSTITUTE, INC. (US) 2022-11-15 — — US disclosed
US-11434248-B2 PDE9 inhibitor and use thereof NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) 2022-09-06 — — US disclosed
US-20220089593-A1 PDE9 INHIBITOR AND USE THEREOF TRANSTHERA SCIENCES (NANJING), INC. (CN) 2022-03-24 — — US disclosed
US-20220089593-A1 PDE9 INHIBITOR AND USE THEREOF TRANSTHERA SCIENCES (NANJING), INC. (CN) 2022-03-24 — — US disclosed
WO-2008084300-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE PFIZER PRODUCTS INC. (US) 2008-07-17 — — WO disclosed
US-20080064682-A1 Pyrazole Derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-03-13 — — US disclosed
EP-1762568-A1 PYRAZOLE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-14 — — EP disclosed
EP-1318978-B1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LAB (US) 2006-02-08 — — EP disclosed
US-6720338-B2 BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL ABBOTT LABORATORIES 2004-04-13 — — US disclosed
EP-1318978-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS Abbott Laboratories (US) 2003-06-18 — — EP disclosed
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters ABBVIE INC. 2002-07-04 — — US disclosed
US-20020055631-A1 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES 2002-05-09 — — US disclosed
WO-2002024636-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2002-03-28 — — WO disclosed
CN-1290251-A N-acyl cyclic amine derivatives BANYU PHARMA CO LTD (JP) 2001-04-04 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 USP2 1839/4885SMN1; SMN2 1440/4885HPGD 2505/4885
US-11498896-B2 Dopamine D2 receptor ligands DRD2, SLC6A3, NTSR2 USP2 1115/4885SMN1; SMN2 1443/4885HPGD 2049/4885
US-20020055631-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 USP2 1819/4885SMN1; SMN2 1656/4885HPGD 2709/4885
US-20230143552-A1 DOPAMINE D2 RECEPTOR LIGANDS DRD2, SLC6A3, NTSR2 USP2 1115/4885SMN1; SMN2 1443/4885HPGD 2049/4885
US-20080064682-A1 Pyrazole Derivatives NAT1, AR, CBR3 USP2 3366/4885SMN1; SMN2 3660/4885HPGD 1996/4885
US-11434248-B2 PDE9 inhibitor and use thereof PDE3A, PDE9A, PDE3B USP2 1674/4885SMN1; SMN2 2269/4885HPGD 459/4885
US-20230183237-A1 COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 CHRM5, CHRM1, CHRM2 USP2 2706/4885SMN1; SMN2 3044/4885HPGD 3255/4885
US-12428373-B2 Dopamine D2 receptor ligands DRD2, SLC6A3, NTSR2 USP2 1115/4885SMN1; SMN2 1443/4885HPGD 2049/4885
US-20220089593-A1 PDE9 INHIBITOR AND USE THEREOF PDE9A, PDE12, PDE5A USP2 2339/4885SMN1; SMN2 2129/4885HPGD 209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.